Supernus Pharmaceuticals Launches Oxtellar XR™ in the United States

ROCKVILLE, Md., Feb. 1, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that Oxtellar XR tablets are now available for sale in the US. Oxtellar XR is a novel once-daily extended release antiepileptic drug indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age. The product has been shipped to major wholesalers in the market, and the Company's sales force of approximately 75 sales representatives will start promoting the product on February 4.

Back to news